Abstract
We evaluated the therapeutic effects of topical administration of 1% cyclosporin A on herpetic stromal keratitis. Sixteen eyes of 16 patients with non-necrotizing herpetic stromal keratitis were divided into two groups according to the use of topical cyclosporin A and retrospectively reviewed. Symptom duration, visual acuity, stromal haziness, and time to improvement of stromal inflammation were analyzed. Eight eyes of 8 patients were treated with 1% cyclosporin A eyedrops in addition to conventional medication and other 8 patients (8 eyes) with conventional treatment only. There were no differences in pre-treatment symptom duration, visual acuity and stromal haziness between two groups. In cyclosporin A treatment group, visual acuity (p=0.018) and stromal haziness (p=0.034) were significantly improved after treatment. There were no differences in time to improvement of stromal inflammation (p=0.798) and post-treatment visual acuity (p=0.234) between two groups, but post-treatment stromal haziness (p=0.038) significantly improved in cyclosporin A treatment group than in conventional treatment group. Topical cyclosporin A may be effectively used in treatment of herpetic stromal keratitis for reducing stromal haziness.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
